Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2126 - 2150 of 3252 in total

CRA_10655

Experimental

MF101

MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational

AM103

AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation. It is being developed by Amira.
Investigational

Fx-1006A

Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational

ACTUS-101

Investigational

RHCC10

RHCC10 is a recombinant human Clara cell protein.
Investigational
Matched Synonyms: … Recombinant human Clara cell 10 kDa protein …

Treprostinil palmitil

Investigational

H3B-8800

H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational

CRA_10991

Experimental

CRA_10762

Experimental

RB106

Experimental

CRA_10972

Experimental

CRA_10656

Experimental

TG-100801

TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational

CPG 10101

CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
Investigational
Matched Description: … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could …

KB109

KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Investigational

P-BCMA-101

P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational

AP103

AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational

INBRX-101

INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein.
Investigational

NN344

NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Investigational
Matched Description: … NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection …

Anti-SARS-CoV-2 REGN-COV2

Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered...
Investigational

Cholesteryl Linoleate

Experimental

Skf 107457

Experimental

ILY101

ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate. ILY101 is designed to allow...
Investigational

ADL 10-0101

ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at...
Investigational
Matched Name: … ADL 10-0101 …
Matched Description: … ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment ... Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic …
Displaying drugs 2126 - 2150 of 3252 in total